Targeting synaptic dysfunction in Alzheimer's disease therapy. - Wikidata - awgldk - TriplyDB

Targeting synaptic dysfunction in Alzheimer's disease therapy.

Targeting synaptic dysfunction in Alzheimer's disease therapy.

http://www.wikidata.org/entity/Q38036916

about

Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease Profile of gantenerumab and its potential in the treatment of Alzheimer's disease Computational identification of potential multitarget treatments for ameliorating the adverse effects of amyloid-β on synaptic plasticity Traumatic brain injury dysregulates microRNAs to modulate cell signaling in rat hippocampus.Aβ-dependent reduction of NCAM2-mediated synaptic adhesion contributes to synapse loss in Alzheimer's disease.Longitudinal testing of hippocampal plasticity reveals the onset and maintenance of endogenous human Aß-induced synaptic dysfunction in individual freely behaving pre-plaque transgenic rats: rapid reversal by anti-Aß agents.Systemic administration of substance P recovers beta amyloid-induced cognitive deficits in rat: involvement of Kv potassium channels.Amyloid-β(25-35) Modulates the Expression of GirK and KCNQ Channel Genes in the Hippocampus.Pharmacological Selectivity Within Class I Histone Deacetylases Predicts Effects on Synaptic Function and Memory Rescue.Bv8/prokineticin 2 is involved in Aβ-induced neurotoxicity Mesenchymal Stem Cells Preserve Working Memory in the 3xTg-AD Mouse Model of Alzheimer's Disease.A novel recombinant 6Aβ15-THc-C chimeric vaccine (rCV02) mitigates Alzheimer's disease-like pathology, cognitive decline and synaptic loss in aged 3 × Tg-AD mice.SUMO and Alzheimer's disease.Synaptic plasticity in multiple sclerosis and in experimental autoimmune encephalomyelitis.Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.Neuroprotective effects of CD4+CD25+Foxp3+ regulatory T cells in a 3xTg-AD Alzheimer's disease model.Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future.Targeting SUMO-1ylation Contrasts Synaptic Dysfunction in a Mouse Model of Alzheimer's Disease.Synaptoimmunology - roles in health and disease.Natural Dietary Supplementation of Anthocyanins via PI3K/Akt/Nrf2/HO-1 Pathways Mitigate Oxidative Stress, Neurodegeneration, and Memory Impairment in a Mouse Model of Alzheimer's Disease.Interleukin-1β promotes long-term potentiation in patients with multiple sclerosis.Electrophysiological Techniques for Studying Synaptic Activity In Vivo.Calcineurin inhibition rescues early synaptic plasticity deficits in a mouse model of Alzheimer's disease.Biobran/MGN-3, an arabinoxylan rice bran, enhances NK cell activity in geriatric subjects: A randomized, double-blind, placebo-controlled clinical trial.

P2860

Q26853610-C88D2579-44D8-454A-B217-A808B3A7917E Q27027675-9814AF91-8B0E-465E-834A-D89C5A8B6A29 Q33611723-7004EA5C-E6BF-4ACA-8AA0-9B9A55917B91 Q33999747-4D8C47E8-2F4F-47F7-9877-7F86212163F9 Q34503220-7ADA5E48-AE0A-4BCD-ADF0-C4076B86FF9D Q34950867-3AC9E183-5D68-41A6-9DE0-624AC1638E99 Q35050266-1F59DFAF-50F8-42A5-A2CA-00B0F5A15B44 Q35719617-906BBE02-0F09-4116-9F93-59A763C62C63 Q35960375-55B906EC-4FBA-47E9-9DF4-9DA2A6FF0FB5 Q36174802-B57CAFDA-9C5E-430B-AB3C-499900DE43E9 Q36666929-4492C5F5-78F2-4F16-829C-F5489A000376 Q36964826-1D5B8721-8F28-4CBA-974B-82C304DD897F Q37297379-0C1802E3-9854-469C-A39F-5CE3BF23599F Q37350716-E6717254-07C4-44A0-9B4B-4AD1A1321B7E Q37559812-2EA37C5B-C362-4A2B-9989-D6FAEBB8B5FB Q37688368-86257414-8D09-4B19-80DF-0E37ED3455FD Q38299414-3B37F417-14EE-4210-BE67-1EACFAED80C1 Q38979988-FF55EF76-9DD5-4167-A9D8-C29DDB005604 Q39388657-5BDC529C-BB84-4FC7-BF3A-45F10AAF4A02 Q46254945-4262A8AA-3986-49C8-AD85-844EDC679DA5 Q46899417-2542FB1B-33D8-4B59-8EAB-8A83B0DC0D20 Q47931622-FE1F2CFD-4D79-4D96-A4B5-76B115A4346F Q48454178-E3A34A85-A0FC-4F13-A259-4D0CFF669392 Q49884471-9C30DE97-751E-4AE5-BB37-8C5C3AC9CCE1

P2860

Targeting synaptic dysfunction in Alzheimer's disease therapy.

http://www.wikidata.org/entity/Q38036916

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Targeting synaptic dysfunction in Alzheimer's disease therapy.

@en

type

label

Targeting synaptic dysfunction in Alzheimer's disease therapy.

@en

prefLabel

Targeting synaptic dysfunction in Alzheimer's disease therapy.

@en

P1433

Q38036916-31BE760A-DF49-47DC-9A8D-F5128B4C8F2D

P1476

Q38036916-4B145ADB-C57F-4C18-9E16-A77AF1ABB74F

P2093

Q38036916-4411B1A4-8031-47EA-8E33-F139347ECDA4

Q38036916-AD4843A0-789D-4CD4-9CFD-DF92BD9ABC7C

P2860

Q38036916-00811D3E-5BF2-4FF8-A39F-424198403A1A

Q38036916-0351B058-3042-4794-9EC7-DD2C671AE999

Q38036916-04DFF437-5069-43ED-988A-D84DAC5BABF0

Q38036916-06122684-F3F6-4B8A-9EFA-4538DC597BE0

Q38036916-06B5D2ED-E6F5-48CF-8ABB-458AEF4874E1

Q38036916-0701D29F-FBB2-4B99-802D-6333610DE6C3

Q38036916-07198D0A-F689-4052-93E3-EA217B2758D0

Q38036916-0A23948B-BD61-41FD-81DA-6057DA70EA4E

Q38036916-0BACF659-56AB-4828-BE4E-685408B48286

Q38036916-0D401D26-0391-4ACC-991D-8ED8675E9980

P2888

Q38036916-3B1FA1B5-9D40-40DA-819F-DDDDFDC705F3

P304

Q38036916-EEF27CF9-C8C7-4087-9342-B5557CC0EB1E

P31

Q38036916-40B8C60E-CA72-4F61-A188-1BE746767568

P356

Q38036916-D4ACBE1A-AE6A-42E1-ABF5-F92AC7879384

P433

Q38036916-267DB8A4-3030-4CCC-A7DC-CD5BDE929E22

P478

Q38036916-1F82C9CA-3E3E-4A52-875B-9881B5581490

P50

Q38036916-098CC78F-35AD-4F08-BE31-3484710FC48C

Q38036916-CC69CA06-09B7-4C8B-80D0-200E0A2DA300

Q38036916-CE1244BC-877A-4F9A-AF84-A57EDA3DCD31

P577

Q38036916-571EFC3C-13CA-47B5-B89B-20AB598C8ABA

P6179

Q38036916-4CEC4895-70E4-43B2-8FE5-2E9D81415062

P698

Q38036916-972793E2-D6CC-4C4F-8145-5117BE526AF9

P921

Q38036916-49FE7F17-BEB8-405C-B3C4-220D30EB567F

P356

S12035-012-8324-3

P1433

Molecular Neurobiology

P1476

Targeting synaptic dysfunction in Alzheimer's disease therapy

@en

P2093

Graham Collingridge

http://www.w3.org/2001/XMLSchema#string

Marco Pignatelli

http://www.w3.org/2001/XMLSchema#string

P2860

A Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers

A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta

Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein

Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model

GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin

Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1

P2888

s12035-012-8324-3

P304

572-587

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12035-012-8324-3

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

Nicola B. Mercuri

P577

2012-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1009923984

http://www.w3.org/2001/XMLSchema#string

P698

22914888

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease